In a large randomized study, the immunotherapy drug nivolumab, a checkpoint inhibitor, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed. Results of the phase III clinical study conducted by physician-scientists at multiple centers, including Roswell Park Cancer Institute (RPCI), will be presented at the American Society of Clinical Oncology (ASCO) 52nd Annual Meeting in Chicago.

Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents. The results of a study led by researchers at Roswell Park Cancer Institute (RPCI) and Columbia University Medical Center used advanced imaging methods to evaluate obesity and suggest a relationship between obesity and disease relapse. The team’s findings will be presented at the American Society of Clinical Oncology (ASCO) 52nd Annual Meeting in Chicago.

While several clinical trials have demonstrated that maintenance therapy with lenalidomide reduces the risk of disease progression in patients with multiple myeloma, there have been no definitive results regarding overall survival. Philip McCarthy, MD, Director of Blood & Marrow Transplant at Roswell Park Cancer Institute, will present the findings of an international team of researchers at the American Society of Clinical Oncology 52nd Annual Meeting in Chicago.

More than two dozen Roswell Park physicians and researchers will be take part in the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago June 3–7, presenting research findings, leading sessions and connecting with colleagues from around the world.

An immune-based therapy developed at Roswell Park Cancer Institute (RPCI) is moving forward with its third clinical trial. The early-stage clinical trial will assess whether SurVaxM — a cancer vaccine developed at Roswell Park — is a safe and effective treatment option for patients with multiple myeloma, a rare type of blood cancer.

Researchers in the Center for Immunotherapy at Roswell Park Cancer Institute (RPCI) have evaluated the human leukocyte antigen (HLA), a group of genes that help regulate the body’s immune system, for underlying differences in ovarian cancer patients’ response to therapy. The

Only 12% of kidney cancer patients with advanced disease survive five years after their initial treatment. In a Roswell Park Cancer Institute-led study, scientists report that some patients with advanced kidney cancer who continued to receive a novel immunotherapy drug after their disease progressed saw clinical benefit.